SEC Form 4 · accession 0001562180-19-000490
Sage Therapeutics, Inc. · SAGE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Elizabeth Barrett
Director
Period of report
Jan 22, 2019
Accepted (ET)
Jan 24, 2019 · 5:29 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001597553
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (Right to buy)F1 | $137.29 | Jan 22, 2019 | A | 20,000 | A | — | Jan 22, 2029 | Common Stock | 20,000 | 20,000 | D |
Explanation of responses
- F1All of the shares subject to the option vest in equal monthly installments during the 36 months following January 22, 2019 (the "Grant Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Grant Date, subject to the reporting person's continued service as a director of the issuer through such date.